Compare URBN & SRRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | URBN | SRRK |
|---|---|---|
| Founded | 1970 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.2B | 6.8B |
| IPO Year | 1995 | 2018 |
| Metric | URBN | SRRK |
|---|---|---|
| Price | $74.82 | $49.85 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 13 |
| Target Price | ★ $86.91 | $56.17 |
| AVG Volume (30 Days) | 1.2M | ★ 1.8M |
| Earning Date | 05-20-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 18.78 | N/A |
| EPS | ★ 4.06 | N/A |
| Revenue | ★ $6,165,376,000.00 | N/A |
| Revenue This Year | $10.67 | N/A |
| Revenue Next Year | $7.01 | $534.24 |
| P/E Ratio | $18.48 | ★ N/A |
| Revenue Growth | ★ 11.07 | N/A |
| 52 Week Low | $59.54 | $27.07 |
| 52 Week High | $85.43 | $61.76 |
| Indicator | URBN | SRRK |
|---|---|---|
| Relative Strength Index (RSI) | 45.97 | 45.98 |
| Support Level | $73.24 | $45.81 |
| Resistance Level | $77.81 | $51.55 |
| Average True Range (ATR) | 2.09 | 2.62 |
| MACD | -0.52 | -0.62 |
| Stochastic Oscillator | 12.19 | 44.69 |
Founded in 1970, Philadelphia-based Urban Outfitters is a multibrand apparel and home goods retailer that operates nearly 800 stores and e-commerce in the US, which accounts for about 87% of sales, as well as in other regions. Its retail nameplates are Urban Outfitters (22% of fiscal 2026 sales), Free People/Movement (26%), and Anthropologie (42%). Retail accounted for 86% of fiscal 2026 revenue, but Urban Outfitters also sells products through a wholesale operation, owns some restaurants, and operates a fast-growing clothing rental and resale business called Nuuly (9% of sales). Urban Outfitters primarily markets to young adults and offers products across apparel (66% of sales), home goods (16% of sales), accessories (13% of sales), and more.
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.